Global Health Updates: Bavarian Nordic's Mpox Vaccine Production, Oropouche Virus Alert, India's Spice Contamination

This article summarizes recent health developments, including Bavarian Nordic ramping up mpox vaccine production, a U.S. CDC warning about Oropouche virus in the Americas, and India's spice contamination issues. Bavarian Nordic aims to manufacture 10 million doses by 2025. The Oropouche virus has caused two deaths, and 12% of Indian spice samples failed safety standards.

Bavarian Nordic, a Danish biotechnology firm, announced plans to significantly increase the production of its mpox vaccine. The company aims to produce 10 million doses by 2025, responding to the global public health emergency. Furthermore, Bavarian Nordic promises fair access, particularly in collaboration with international health organizations.

In another health-related development, the U.S. Centers for Disease Control and Prevention has issued a health alert regarding the spread of the Oropouche virus across the Americas. The virus, transmitted by infected midges and mosquitoes, has resulted in two fatalities this year. Symptoms include headache, fever, and muscle aches, with severe cases leading to meningitis.

Meanwhile, almost 12% of tested spice samples in India have failed to meet quality and safety standards, as per data acquired by Reuters. This follows steps taken by several countries over contamination concerns. The Food Safety and Standards Authority of India conducted extensive testing, especially after mixed spice blends from the MDH and Everest brands were found to contain high levels of pesticide, leading to a suspension of sales in Hong Kong.

(With inputs from agencies.)